{"id":"escharex-ex-03","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or erythema at application site"},{"rate":null,"effect":"Bleeding or oozing from debrided wound"},{"rate":null,"effect":"Pain at application site"}]},"_chembl":{"chemblId":"CHEMBL5908142","moleculeType":null,"molecularWeight":"440.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EscharEx contains a purified mixture of proteolytic enzymes derived from bromelain that digest and break down dead, damaged tissue (eschar) while preserving healthy tissue. This selective enzymatic debridement promotes faster wound healing and reduces the need for surgical intervention in burn patients.","oneSentence":"EscharEx is a topical enzymatic debriding agent that selectively removes necrotic tissue from burns and wounds.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:21.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thermal burns requiring eschar removal"},{"name":"Enzymatic debridement of burn wounds"}]},"trialDetails":[{"nctId":"NCT06568627","phase":"PHASE3","title":"A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)","status":"RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-06-01","conditions":"Venous Leg Ulcer (VLU)","enrollment":216},{"nctId":"NCT06690177","phase":"PHASE2","title":"Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers","status":"NOT_YET_RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-04-30","conditions":"Venus Leg Ulcers","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EX-03"],"phase":"phase_3","status":"active","brandName":"EscharEx (EX-03)","genericName":"EscharEx (EX-03)","companyName":"MediWound Ltd","companyId":"mediwound-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EscharEx (EX-03) is a treatment being studied for the debridement of Venous Leg Ulcers (VLUs) in a clinical trial. The study, NCT06568627, is a double-blind, placebo-controlled trial comparing EscharEx to a gel vehicle in patients with VLUs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}